%20(1).jpg?w=350&fit=crop&auto=format)
In her Letter to the Readers, co-editor-in-chief of the journal ONCOLOGY Julie M. Vose, MD, MBA, reviews developments from the fourth annual LEAD Conference for women in hematology and oncology.
Julie M. Vose, MD, MBA
Co-Editor in Chief
Professor, Internal Medicine
Chief of Hematology & Oncology, Department of Internal Medicine
University of Nebraska Medical Center College of Medicine
Associate Director of Clinical Research
Fred and Pamela Buffet Cancer Center
Omaha, NE
Julie M. Vose, MD, MBA, is the Neumann M. and Mildred E. Harris professor and the chief of the Division of Oncology/Hematology in the Department of Internal Medicine at University of Nebraska Medical Center (UNMC). Vose graduated from Medical School at UNMC, completed her internal medicine residency as well as a Chief Resident year, followed by a Hematology/Oncology Fellowship at UNMC, and has been on faculty since 1990. Vose is an internationally known leading expert in the treatment of patients with Hodgkin lymphoma, non-Hodgkin lymphoma (NHL), and chronic lymphocytic leukemia. She is actively involved in many novel clinical trials for lymphoma including targeted agents, monoclonal antibodies, and cellular therapy. Vose has been recognized for her NHL research on a national and international level through research awards and invited lectureships worldwide.
Advertisement
Julie M. Vose, MD, MBA, chief of Hematology/Oncology at the Buffett Cancer Center of the University of Nebraska Medical Center, writes about American Board of Internal Medicine Recertification Exams in her monthly "Letter to the Readers."
ONCOLOGY co-editor-in-chief Julie M. Vose, MD, MBA, re-caps the 2021 American Society of Hematology conference and discusses which presentations were the most important.
ONCOLOGY co-editor-in-chief Julie M. Vose, MD, MBA, anticipates how COVID-19 will continue to impact the oncology field.
ONCOLOGY® co-editor-in-chief Julie M. Vose, MD, MBA, recaps the 2021 Leadership, Empowerment, and Development Conference: Enriching and Supporting Women in Hematology and Oncology.
ONCOLOGY® co–editor-in-chief, Julie Vose, discusses how the COVID-19 pandemic has caused physician burnout and what may be done to prevent it.
Julie Vose, MD, MBA, a professor of internal medicine in the Division of Oncology and Hematology at the University of Nebraska Medical Center, discusses novel treatment options for patients with hematologic malignancies at the 2021 American Society of Clinical Oncology Annual Meeting.
Julie Vose, MD, MBA, a professor of internal medicine in the Division of Oncology and Hematology at the University of Nebraska Medical Center discussed the benefits of CAR T-cell for patients with follicular lymphoma.
CancerNetwork® sat down with Julie Vose, MD, MBA, at the 2021 American Society of Clinical Oncology Annual Meeting to talk about a clinical trial comparing acalabrutinib versus ibrutinib for patients with chronic lymphocytic leukemia.
ONCOLOGY® co-Editor-in-Cheif Julie M. Vose, MD, MBA, chief of the Division of Hematology/Oncology at the University of Nebraska Medical Center in Omaha, Nebraska, discusses the emergence of telehealth during the COVID-19 pandemic and the needs of patients going forward.
Advertisement
Advertisement
